These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 32678017)

  • 1. A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID-19 patients: a clinical case report.
    Peng H; Gong T; Huang X; Sun X; Luo H; Wang W; Luo J; Luo B; Chen Y; Wang X; Long H; Mei H; Li C; Dai Y; Li H
    Stem Cell Res Ther; 2020 Jul; 11(1):291. PubMed ID: 32678017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.
    Shen C; Wang Z; Zhao F; Yang Y; Li J; Yuan J; Wang F; Li D; Yang M; Xing L; Wei J; Xiao H; Yang Y; Qu J; Qing L; Chen L; Xu Z; Peng L; Li Y; Zheng H; Chen F; Huang K; Jiang Y; Liu D; Zhang Z; Liu Y; Liu L
    JAMA; 2020 Apr; 323(16):1582-1589. PubMed ID: 32219428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
    Atluri S; Manchikanti L; Hirsch JA
    Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Disillusioned Comfort with COVID-19 and the Potential of Convalescent Plasma and Cell Therapy.
    Borlongan MC; Borlongan MC; Sanberg PR
    Cell Transplant; 2020; 29():963689720940719. PubMed ID: 32841042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.
    Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR
    Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
    Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
    Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Convalescent plasma in Covid-19: Possible mechanisms of action.
    Rojas M; Rodríguez Y; Monsalve DM; Acosta-Ampudia Y; Camacho B; Gallo JE; Rojas-Villarraga A; Ramírez-Santana C; Díaz-Coronado JC; Manrique R; Mantilla RD; Shoenfeld Y; Anaya JM
    Autoimmun Rev; 2020 Jul; 19(7):102554. PubMed ID: 32380316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial.
    Meng F; Xu R; Wang S; Xu Z; Zhang C; Li Y; Yang T; Shi L; Fu J; Jiang T; Huang L; Zhao P; Yuan X; Fan X; Zhang JY; Song J; Zhang D; Jiao Y; Liu L; Zhou C; Maeurer M; Zumla A; Shi M; Wang FS
    Signal Transduct Target Ther; 2020 Aug; 5(1):172. PubMed ID: 32855385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19.
    Mansourabadi AH; Sadeghalvad M; Mohammadi-Motlagh HR; Rezaei N
    Life Sci; 2020 Oct; 258():118185. PubMed ID: 32750438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The resurgence of convalescent plasma therapy.
    The Lancet Haematology
    Lancet Haematol; 2020 May; 7(5):e353. PubMed ID: 32359447
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea.
    Ahn JY; Sohn Y; Lee SH; Cho Y; Hyun JH; Baek YJ; Jeong SJ; Kim JH; Ku NS; Yeom JS; Roh J; Ahn MY; Chin BS; Kim YS; Lee H; Yong D; Kim HO; Kim S; Choi JY
    J Korean Med Sci; 2020 Apr; 35(14):e149. PubMed ID: 32281317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in the research of mechanism and related immunotherapy on the cytokine storm induced by coronavirus disease 2019].
    Chen C; Zhang XR; Ju ZY; He WF
    Zhonghua Shao Shang Za Zhi; 2020 Jun; 36(6):471-475. PubMed ID: 32114747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia.
    Zhang Y; Ding J; Ren S; Wang W; Yang Y; Li S; Meng M; Wu T; Liu D; Tian S; Tian H; Chen S; Zhou C
    Stem Cell Res Ther; 2020 May; 11(1):207. PubMed ID: 32460839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent plasma treatment for COVID-19: Tempering expectations with the influenza experience.
    Subbarao K; Mordant F; Rudraraju R
    Eur J Immunol; 2020 Oct; 50(10):1447-1453. PubMed ID: 32886952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-optimal effectiveness of convalescent plasma transfusion and hydroxychloroquine in treating COVID-19: a case report.
    Xu TM; Lin B; Chen C; Liu LG; Xue Y
    Virol J; 2020 Jun; 17(1):80. PubMed ID: 32560646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19.
    Zhang L; Pang R; Xue X; Bao J; Ye S; Dai Y; Zheng Y; Fu Q; Hu Z; Yi Y
    Aging (Albany NY); 2020 Apr; 12(8):6536-6542. PubMed ID: 32320384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy assessment of convalescent plasma therapy for COVID-19 patients: a multi-center case series.
    Zeng H; Wang D; Nie J; Liang H; Gu J; Zhao A; Xu L; Lang C; Cui X; Guo X; Zhou C; Li H; Guo B; Zhang J; Wang Q; Fang L; Liu W; Huang Y; Mao W; Chen Y; Zou Q
    Signal Transduct Target Ther; 2020 Oct; 5(1):219. PubMed ID: 33024082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INFUSION OF CONVALESCENT PLASMA IS ASSOCIATED WITH CLINICAL IMPROVEMENT IN CRITICALLY ILL PATIENTS WITH COVID-19: A PILOT STUDY.
    Olivares-Gazca JC; Priesca-Marín JM; Ojeda-Laguna M; Garces-Eisele J; Soto-Olvera S; Palacios-Alonso A; Izquierdo-Vega J; Chacon-Cano R; Arizpe-Bravo D; López-Trujillo MA; Cantero-Fortiz Y; Fernandez-Lara D; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
    Rev Invest Clin; 2020; 72(3):159-164. PubMed ID: 32584322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic potential of convalescent plasma therapy on treating critically-ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad, Iraq.
    Rasheed AM; Fatak DF; Hashim HA; Maulood MF; Kabah KK; Almusawi YA; Abdulamir AS
    Infez Med; 2020 Sep; 28(3):357-366. PubMed ID: 32920571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: an Immunopathological View.
    Kadkhoda K
    mSphere; 2020 Apr; 5(2):. PubMed ID: 32321823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.